Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Stefanie L. Groenland*, Dieuwertje R. Geel, Jos H. Beijnen, Egbert F. Smit, Alwin D.R. Huitema, Neeltje Steeghs

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)1164-1164
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume110
Issue number5
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Carbazoles
  • Humans
  • Lung Neoplasms/drug therapy
  • Piperidines/adverse effects
  • Receptor Protein-Tyrosine Kinases

Cite this